BioSpace News Archive

Taysha Gene Therapies, Inc. today announced two poster presentations at the upcoming 29th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT) in cooperation with the British Society of Gene & Cell Therapy (BSGCT) taking place in Edinburgh, Scotland from October 11-14, 2022.

Zynerba Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,458,110, titled “Treatment of Fragile X Syndrome With Cannabidiol,” which includes claims directed to methods of treating Fragile X syndrome with cannabidiol.

SOPHiA GENETICS today announced it will release its financial results for the third quarter of fiscal 2022 before U.S. markets open on Tuesday, November 8, 2022.

Microbix Biosystems Inc. will present results of novel methods to support diagnostic accuracy and whole-process workflow validation of cervical cancer screening tests on self-collected patient specimens.

AN2 Therapeutics, Inc. today provided an update on the ex-U.S. development plan for epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease, the most common form of non-tuberculous mycobacterial (NTM) lung disease.

Applied Therapeutics, Inc. today announced that the ACTION-Galactosemia Kids Phase 3 trial has demonstrated a trend in clinical benefit favoring AT-007 vs. placebo.

Plus Therapeutics, Inc. announced that the Company will report third quarter 2022 financial results on Thursday, October 20, 2022, after market close.

NexImmune, Inc. today announced a collaboration with the National Institute of Neurological Disorders and Stroke (NINDS), a division of the U.S. National Institutes of Health (NIH).

Entera Bio Ltd. conclusion of its Type C meeting and agreement from the U.S. Food and Drug Administration (FDA) that a single Phase 3 placebo-controlled study could support a New Drug Application (NDA) submission of EB613.

Bio-Techne Corporation (NASDAQ: TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ in situ hybridization (ISH) portfolio with the release of new automated co-detection assays specifically designed for the Roche DISCOVERY ULTRA Platform, enabling simultaneous detection of RNA and protein on the same tissue section.